MedTrace Logo

Using Gum Arabic for Cancer Patients to Protect From Oral Mucositis Caused by Chemotherapy: ِِِAn Experimental Study

NCT03348241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 386

Last updated 2017-11-20

No results posted yet for this study

Summary

This study was designed to investigate the effect of Gum Arabic (GA) on cancer patients to prevent chemotherapy-induced oral mucositis. Cancer patients who will receive chemotherapy were divided into two groups; study "Gum Arabic" group (which received GA with chemotherapy) and control group (chemotherapy alone); and the participants were recruited to reach 190 patients in the study group and 184 patients in control group. This clinical trial was conducted in outpatient chemotherapy sections at Radiation and Isotopes Center of Khartoum. This study was designed to test the theory that say the chemotherapy-induced oral mucositis will significantly decrease after ingestion 30 grams as daily dose of Gum Arabic in a form of solution for six weeks during therapy.

Conditions

  • Chemotherapy-induced Oral Mucositis

Interventions

DRUG

Gum Arabic

Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.

DRUG

Chemotherapy

Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.

BEHAVIORAL

Lifestyle counseling

Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.

Sponsors & Collaborators

  • University of Science and Technology, Yemen

    lead OTHER

Principal Investigators

  • Abdulrazzaq Y. Al khazzan, MClinPharm · University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
83 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-26
Primary Completion
2016-08-31
Completion
2016-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03348241 on ClinicalTrials.gov